Search

Displaying results 3261 - 3270 of 10000 in total
  1. Drug

    Meglumine

    go.drugbank.com/drugs/DB09415
    ApprovedInvestigational

    Synonyms: N-methyl-D-glucamineCategories: Compounds used in a research, industrial, or household setting
  2. Drug

    Estriol

    go.drugbank.com/drugs/DB04573
    ApprovedInvestigationalVet approved

    It is however available in the United States by prescription filled only by compounding pharmacies.

    International brands: Synapause E
  3. Drug

    Imidafenacin

    go.drugbank.com/drugs/DB09262
    Investigational

    Imidafenacin is an antispasmodic agent with anticholinergic effects. It antagonizes muscarinic receptors in the bladder to reduce the frequency of urination in the treatment of overactive bladder. … It is marketed in Japan under the tradenames Staybla by Ono Pharmaceutical and Uritos by Kyojin Pharmaceutical.

  4. Drug

    Mepenzolate

    go.drugbank.com/drugs/DB04843
    ApprovedWithdrawn

    It has not been shown to be effective in contributing to the healing of peptic ulcer, decreasing the rate of recurrence, or preventing complications.

  5. Drug

    Coagulation Factor IX (Recombinant)

    go.drugbank.com/drugs/DB00100
    Approved

    Recombinant Factor IX is indicated for the control and prevention of bleeding episodes in adult and pediatric patients with congenital factor IX deficiency (Hemophilia B). … It is not derived from human blood (unlike human Factor IX complex), and is instead produced by a genetically engineered Chinese hamster ovary (CHO) cell line that secretes recombinant Factor IX into cell

  6. Drug

    Rapacuronium

    go.drugbank.com/drugs/DB04834
    ApprovedWithdrawn

    Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.

  7. Drug

    Nitrendipine

    go.drugbank.com/drugs/DB01054
    ApprovedWithdrawn

    It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.

  8. Drug

    Tabelecleucel

    go.drugbank.com/drugs/DB17072
    ApprovedInvestigational

    Tabelecleucel is an innovative therapy that uses Epstein-Barr virus (EBV)-specific allogeneic cytotoxic T cells (CTLs). … [A253292,A253297,L43557] In October 2022, the EMA's Committee for Medicinal Products for Human Use (CHMP) recommended tabelecleucel be granted marketing authorization for the treatment of adult and

  9. Drug

    Oglufanide

    go.drugbank.com/drugs/DB05779
    Investigational

    Oglufanide was originally developed to treat severe infectious disease in Russia (where it is a registered pharmaceutical), and was extensively studied in cancer clinical trials in the United States before … being acquired by Implicit Bioscience in 2005.

    Categories: Compounds used in a research, industrial, or household setting
  10. Drug

    Olaratumab

    go.drugbank.com/drugs/DB06043
    ApprovedInvestigational

    Studies show that the treatment of olaratumab in combination with doxorubicin resulted in significant reduction of cancer cell proliferation and tumor growth. … Olaratumab was granted accelerated approval (as Lartruvo) as initial therapy to treat adults with certain types of soft tissue sarcoma (STS) in October, 2016.